Patents by Inventor Neil Beeharry

Neil Beeharry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apilimod compositions and methods for using same
    Patent number: 11266654
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 8, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • Apilimod compositions and methods for using same in the treatment of renal cancer
    Patent number: 11166944
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: November 9, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • PIKFYVE INHIBITORS FOR CANCER THERAPY
    Publication number: 20210077500
    Abstract: The present disclosure relates methods for treating a cancer having activated MET or RAS pathway signaling using an inhibitor of PIKfyve, alone or in combination with a MET inhibitor or a RAS pathway inhibitor, and related compositions and methods to identify PIKfyve inhibitor sensitive cancers for targeted treatment.
    Type: Application
    Filed: September 10, 2020
    Publication date: March 18, 2021
    Inventors: Sean Landrette, Neil Beeharry, Peter R. Young, Jonathan M. Rothberg, Tian Xu, Henri Lichenstein
  • METHOD FOR TREATING CANCER USING HSP90 INHIBITORS
    Publication number: 20210030759
    Abstract: The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of ‘low dose’ HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.
    Type: Application
    Filed: September 23, 2020
    Publication date: February 4, 2021
    Inventors: Neil Beeharry, Marylens Hernandez, Sean Landrette, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOF
    Publication number: 20200360397
    Abstract: The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apilimod and at least one additional anti-viral agent.
    Type: Application
    Filed: July 1, 2020
    Publication date: November 19, 2020
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad
  • Methods for treating cancer using HSP90 inhibitors
    Patent number: 10799508
    Abstract: The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of ‘low dose’ HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: October 13, 2020
    Assignee: A1 Therapeutics, Inc.
    Inventors: Neil Beeharry, Marylens Hernandez, Sean Landrette, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • APILIMOD COMPOSITIONS AND METHODS FOR USING SAME IN THE TREATMENT OF RENAL CANCER
    Publication number: 20200297706
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Application
    Filed: November 26, 2019
    Publication date: September 24, 2020
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Apilimod for use in the treatment of melanoma
    Patent number: 10765682
    Abstract: The present invention relates to methods for treating melanoma with apilimod and related compositions and methods.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: September 8, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • APILIMOD COMPOSITIONS AND METHODS FOR USING SAME
    Publication number: 20200268764
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Application
    Filed: December 27, 2019
    Publication date: August 27, 2020
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • THERAPEUTIC METHODS RELATING TO HSP90 INHIBITORS
    Publication number: 20200253979
    Abstract: The disclosure provides methods for treating cancer, including but not limited to, hematopoietic and lung cancers, using the HSP90 inhibitor, MPC-0767, as monotherapy and in combination therapy with additional active agents, including but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoint inhibitors, DNMT inhibitors, ATO and chemotherapeutic agents. The disclosure also provides related compositions and methods of use.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 13, 2020
    Inventors: Henri Lichenstein, Neil Beeharry, Sean Landrette, Sophia Gayle, Jeff Grotzke, Marylens Hernandez, Peter R. Young, Jonathan M. Rothberg
  • Anti-viral compositions containing PIKfyve inhibitors and use thereof
    Patent number: 10729694
    Abstract: The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apillimod and at least one additional anti-viral agent.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 4, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad
  • Methods for treating cancer using apilimod
    Patent number: 10350213
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: July 16, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Tian Xu
  • APILIMOD FOR USE IN THE TREATMENT OF RENAL CANCER
    Publication number: 20190201385
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Application
    Filed: December 19, 2018
    Publication date: July 4, 2019
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Apilimod Compositions and Methods for Using Same
    Publication number: 20190183902
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Application
    Filed: November 16, 2018
    Publication date: June 20, 2019
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • THERAPEUTIC METHODS RELATING TO HSP90 INHIBITORS
    Publication number: 20190091229
    Abstract: The disclosure provides methods for treating cancer, including but not limited to, hematopoietic and lung cancers, using the HSP90 inhibitor, MPC-0767, as monotherapy and in combination therapy with additional active agents, including but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoint inhibitors, DNMT inhibitors, ATO and chemotherapeutic agents. The disclosure also provides related compositions and methods of use.
    Type: Application
    Filed: September 27, 2018
    Publication date: March 28, 2019
    Inventors: Henri Lichenstein, Neil Beeharry, Sean Landrette, Sophia Gayle, Jeff Grotzke, Marylens Hernandez, Peter R. Young, Jonathan M. Rothberg
  • Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
    Patent number: 10220051
    Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 5, 2019
    Inventors: Alfonso Bellacosa, Timothy Yen, Neil Beeharry, Mitchell Smith, Rossella Tricarico, Vikram Bhattacharjee, Pietro Mancuso
  • Apilimod for use in the treatment of renal cancer
    Patent number: 10206910
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: February 19, 2019
    Assignee: LAM Therapeutics, Inc.
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Biomarkers for Treating Cancer with Apilimod
    Publication number: 20190015421
    Abstract: The present disclosure relates to compositions and methods for treating cancer in a subject having cancer cells over-expressing a microphthalmia (MiT) transcription factor with apilimod and related compositions and methods.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 17, 2019
    Inventors: Sophia Gayle, Neil Beeharry, Sean Landrette, Chris Conrad, Paul Beckett, Marylens Hernandez, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Apilimod compositions and methods for using same
    Patent number: 10179135
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: January 15, 2019
    Assignee: LAM Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • Methods for treating cancer using HSP90 inhibitors
    Publication number: 20180221376
    Abstract: The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of low dose' HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 9, 2018
    Inventors: Neil Beeharry, Marylens Hernandez, Sean Landrette, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein